Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

A Multiplex Quantitative Reverse Transcription Polymerase Chain Reaction Assay for the Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pilocytic Astrocytomas.

Bret D, Chappuis V, Poncet D, Ducray F, Silva K, Mion F, Vasiljevic A, Ferraro-Peyret C, Mottolese C, Leblond P, Gabut M, Frappaz D, Streichenberger N, Meyronet D, Bringuier PP, Barritault M.

Mol Diagn Ther. 2019 May 13. doi: 10.1007/s40291-019-00403-3. [Epub ahead of print]

PMID:
31087282
2.

Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age.

Castet F, Alanya E, Vidal N, Izquierdo C, Mesia C, Ducray F, Gil-Gil M, Bruna J.

J Neurooncol. 2019 May 3. doi: 10.1007/s11060-019-03183-2. [Epub ahead of print]

PMID:
31054099
3.

Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature.

Garnier L, Ducray F, Verlut C, Mihai MI, Cattin F, Petit A, Curtit E.

Front Oncol. 2019 Mar 26;9:177. doi: 10.3389/fonc.2019.00177. eCollection 2019.

4.

Simultaneous occurrence of giant cell arteritis and cerebral amyloid angiopathy.

Fouret M, Jamilloux Y, Szathmari A, Vasiljevic A, Meyronet D, Ducray F, Seve P.

Rheumatology (Oxford). 2019 Mar 29. pii: kez099. doi: 10.1093/rheumatology/kez099. [Epub ahead of print] No abstract available.

PMID:
30927437
5.

Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study.

Ursu R, Thomas L, Psimaras D, Chinot O, Le Rhun E, Ricard D, Charissoux M, Cuzzubbo S, Sejalon F, Quillien V, Hoang-Xuan K, Ducray F, Portal JJ, Tibi A, Mandonnet E, Levy-Piedbois C, Vicaut E, Carpentier AF.

Eur J Cancer. 2019 Mar;109:129-136. doi: 10.1016/j.ejca.2018.12.025. Epub 2019 Feb 1.

PMID:
30716716
6.

The molecular landscape of glioma in patients with Neurofibromatosis 1.

D'Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A.

Nat Med. 2019 Jan;25(1):176-187. doi: 10.1038/s41591-018-0263-8. Epub 2018 Dec 10.

PMID:
30531922
7.

Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome.

Vogrig A, Joubert B, Maureille A, Thomas L, Bernard E, Streichenberger N, Cotton F, Ducray F, Honnorat J.

J Neurol. 2019 Feb;266(2):398-410. doi: 10.1007/s00415-018-9143-x. Epub 2018 Nov 29.

PMID:
30498914
8.

Stroke-like events after brain radiotherapy: a large series with long-term follow-up.

Di Stefano AL, Berzero G, Ducray F, Eoli M, Pichiecchio A, Farina LM, Cuccarini V, Brunelli MC, Diamanti L, Condette Auliac S, Salmaggi A, Silvani A, Giometto B, Pace A, Vidiri A, Bourdain F, Bastianello S, Ceroni M, Marchioni E.

Eur J Neurol. 2019 Apr;26(4):639-650. doi: 10.1111/ene.13870. Epub 2019 Jan 10.

PMID:
30471162
9.

Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis.

Maureille A, Fenouil T, Joubert B, Picard G, Rogemond V, Pinto AL, Thomas L, Ducray F, Quadrio I, Psimaras D, Berzero G, Antoine JC, Desestret V, Honnorat J.

J Neurol. 2019 Jan;266(1):195-206. doi: 10.1007/s00415-018-9132-0. Epub 2018 Nov 20.

PMID:
30460450
10.

Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.

Izquierdo C, Barritault M, Poncet D, Cartalat S, Joubert B, Bruna J, Jouanneau E, Guyotat J, Vasiljevic A, Fenouil T, Berthezène Y, Honnorat J, Meyronet D, Ducray F.

Neurosurgery. 2018 Nov 8. doi: 10.1093/neuros/nyy513. [Epub ahead of print]

PMID:
30407589
11.

Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.

Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA network.

Acta Neuropathol Commun. 2018 Sep 7;6(1):89. doi: 10.1186/s40478-018-0594-1.

12.

Molecular classification of adult gliomas: recent advances and future perspectives.

Barritault M, Meyronet D, Ducray F.

Curr Opin Oncol. 2018 Nov;30(6):375-382. doi: 10.1097/CCO.0000000000000482. Review.

PMID:
30148717
13.

Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma.

Rosenberg S, Ducray F, Alentorn A, Dehais C, Elarouci N, Kamoun A, Marie Y, Tanguy ML, De Reynies A, Mokhtari K, Figarella-Branger D, Delattre JY, Idbaih A; POLA Network.

Oncologist. 2018 Dec;23(12):1500-1510. doi: 10.1634/theoncologist.2017-0495. Epub 2018 Jul 17.

PMID:
30018130
14.

Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies.

Bost C, Chanson E, Picard G, Meyronet D, Mayeur ME, Ducray F, Rogemond V, Psimaras D, Antoine JC, Delattre JY, Desestret V, Honnorat J.

J Neurol. 2018 Oct;265(10):2190-2200. doi: 10.1007/s00415-018-8970-0. Epub 2018 Jul 12.

PMID:
30003358
15.

Returning to work after multimodal treatment in glioblastoma patients.

Starnoni D, Berthiller J, Idriceanu TM, Meyronet D, d'Hombres A, Ducray F, Guyotat J.

Neurosurg Focus. 2018 Jun;44(6):E17. doi: 10.3171/2018.3.FOCUS1819.

PMID:
29852767
16.

Motor neuron disease of paraneoplastic origin: a rare but treatable condition.

Mélé N, Berzero G, Maisonobe T, Salachas F, Nicolas G, Weiss N, Beaudonnet G, Ducray F, Psimaras D, Lenglet T.

J Neurol. 2018 Jul;265(7):1590-1599. doi: 10.1007/s00415-018-8881-0. Epub 2018 May 3. Review.

PMID:
29725842
17.

IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.

Appay R, Tabouret E, Macagno N, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA Network.

Neuro Oncol. 2018 Apr 9;20(5):716-718. doi: 10.1093/neuonc/noy014. No abstract available.

18.

Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy.

Bronnimann C, Izquierdo C, Cartalat S, Thomas L, Joubert B, Delpech L, Barritault M, Meyronet D, Honnorat J, Ducray F.

J Neurooncol. 2018 May;138(1):141-145. doi: 10.1007/s11060-018-2780-1. Epub 2018 Jan 31.

PMID:
29388033
19.

Glioblastoma as differential diagnosis of autoimmune encephalitis.

Vogrig A, Joubert B, Ducray F, Thomas L, Izquierdo C, Decaestecker K, Martinaud O, Gerardin E, Grand S, Honnorat J.

J Neurol. 2018 Mar;265(3):669-677. doi: 10.1007/s00415-018-8767-1. Epub 2018 Jan 30.

PMID:
29383516
20.

Characteristics of cerebellar glioblastomas in adults.

Picart T, Barritault M, Berthillier J, Meyronet D, Vasiljevic A, Frappaz D, Honnorat J, Jouanneau E, Poncet D, Ducray F, Guyotat J.

J Neurooncol. 2018 Feb;136(3):555-563. doi: 10.1007/s11060-017-2682-7. Epub 2017 Dec 1.

PMID:
29196927
21.

Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.

Izquierdo C, Alentorn A, Idbaih A, Simó M, Kaloshi G, Ricard D, Barritault M, Meyronet D, Bruna J, Honnorat J, Delattre JY, Ducray F.

J Neurooncol. 2018 Feb;136(3):533-539. doi: 10.1007/s11060-017-2677-4. Epub 2017 Nov 15.

PMID:
29143276
22.

Intravascular large B-cell lymphoma mimicking cerebral amyloid angiopathy-related inflammation.

Leclercq L, Mechtouff L, Hermier M, Cho TH, Nighoghossian N, Ducray F.

Rev Neurol (Paris). 2018 Apr;174(4):265-266. doi: 10.1016/j.neurol.2017.06.023. Epub 2017 Nov 7. No abstract available.

PMID:
29126561
23.

Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies.

Berzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, Rogemond V, Candelier G, Camdessanché JP, Antoine JC, De Seze J, Liou-Schischmanoff A, Honnorat J, Delattre JY, Psimaras D.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):789-792. doi: 10.1136/jnnp-2017-316904. Epub 2017 Oct 30. No abstract available.

24.

Anaplastic gliomas in adults: an update.

Izquierdo C, Joubert B, Ducray F.

Curr Opin Oncol. 2017 Nov;29(6):434-442. doi: 10.1097/CCO.0000000000000409. Review.

PMID:
28901965
25.

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

Quillien V, Lavenu A, Ducray F, Meyronet D, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Cancer Biomark. 2017 Dec 6;20(4):435-441. doi: 10.3233/CBM-170191.

26.

Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis.

Joubert B, Gobert F, Thomas L, Saint-Martin M, Desestret V, Convers P, Rogemond V, Picard G, Ducray F, Psimaras D, Antoine JC, Delattre JY, Honnorat J.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 14;4(4):e371. doi: 10.1212/NXI.0000000000000371. eCollection 2017 Jul.

27.

Characteristics of H3 K27M-mutant gliomas in adults.

Meyronet D, Esteban-Mader M, Bonnet C, Joly MO, Uro-Coste E, Amiel-Benouaich A, Forest F, Rousselot-Denis C, Burel-Vandenbos F, Bourg V, Guyotat J, Fenouil T, Jouvet A, Honnorat J, Ducray F.

Neuro Oncol. 2017 Aug 1;19(8):1127-1134. doi: 10.1093/neuonc/now274.

28.

Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies.

Do LD, Chanson E, Desestret V, Joubert B, Ducray F, Brugière S, Couté Y, Formaglio M, Rogemond V, Thomas-Antérion C, Borrega L, Laurens B, Tison F, Curot J, De Brouker T, Lebrun-Frenay C, Delattre JY, Antoine JC, Honnorat J.

Neurology. 2017 Feb 7;88(6):514-524. doi: 10.1212/WNL.0000000000003586. Epub 2017 Jan 6.

PMID:
28062719
29.

Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.

Fossard G, Ferlay C, Nicolas-Virelizier E, Rey P, Ducray F, Jouanneau E, Faurie P, Belhabri A, Sunyack MP, Chassagne-Clément C, Thiesse P, Sebban C, Biron P, Blay JY, Ghesquières H.

Eur J Cancer. 2017 Feb;72:12-19. doi: 10.1016/j.ejca.2016.10.036. Epub 2016 Dec 22.

PMID:
28012348
30.

Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.

Ollier E, Mazzocco P, Ricard D, Kaloshi G, Idbaih A, Alentorn A, Psimaras D, Honnorat J, Delattre JY, Grenier E, Ducray F, Samson A.

Fundam Clin Pharmacol. 2017 Jun;31(3):347-358. doi: 10.1111/fcp.12259. Epub 2017 Jan 24.

PMID:
27933657
31.

Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas.

Bielle F, Ducray F, Mokhtari K, Dehais C, Adle-Biassette H, Carpentier C, Chanut A, Polivka M, Poggioli S, Rosenberg S, Giry M, Marie Y, Duyckaerts C, Sanson M, Figarella-Branger D, Idbaih A; Pola Network.

Brain Pathol. 2017 Sep;27(5):567-579. doi: 10.1111/bpa.12434. Epub 2016 Oct 28.

PMID:
27543943
32.

Neuroleptic intolerance in patients with anti-NMDAR encephalitis.

Lejuste F, Thomas L, Picard G, Desestret V, Ducray F, Rogemond V, Psimaras D, Antoine JC, Delattre JY, Groc L, Leboyer M, Honnorat J.

Neurol Neuroimmunol Neuroinflamm. 2016 Aug 29;3(5):e280. doi: 10.1212/NXI.0000000000000280. eCollection 2016 Oct.

33.

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.

Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D; For POLA Network.

Acta Neuropathol. 2016 Oct;132(4):625-34. doi: 10.1007/s00401-016-1611-8. Epub 2016 Aug 29.

PMID:
27573687
34.

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.

Quillien V, Lavenu A, Ducray F, Joly MO, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Oncotarget. 2016 Sep 20;7(38):61916-61929. doi: 10.18632/oncotarget.11322.

35.

Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures.

Joubert B, Saint-Martin M, Noraz N, Picard G, Rogemond V, Ducray F, Desestret V, Psimaras D, Delattre JY, Antoine JC, Honnorat J.

JAMA Neurol. 2016 Sep 1;73(9):1115-24. doi: 10.1001/jamaneurol.2016.1585.

PMID:
27428927
36.

Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.

Paquette B, Vernerey D, Chauffert B, Dabakuyo S, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R, Ducray F, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O, Anota A, Bonnetain F.

Cancer Med. 2016 Aug;5(8):1753-64. doi: 10.1002/cam4.734. Epub 2016 Jun 1.

37.

The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.

Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X.

Neuro Oncol. 2016 Aug;18(8):1129-36. doi: 10.1093/neuonc/now102. Epub 2016 May 13.

38.

Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas.

Figarella-Branger D, Mokhtari K, Dehais C, Carpentier C, Colin C, Jouvet A, Uro-Coste E, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Loussouarn D, Lacroix C, Rigau V, Laquerrière A, Vandenbos F, Michalak S, Sevestre H, Peoch M, Labrousse F, Christov C, Kemeny JL, Chenard MP, Chiforeanu D, Ducray F, Idbaih A, Delattre JY; POLA Network.

Neuro Oncol. 2016 Jun;18(6):888-90. doi: 10.1093/neuonc/now085. No abstract available.

39.

Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas.

Kamoun A, Idbaih A, Dehais C, Elarouci N, Carpentier C, Letouzé E, Colin C, Mokhtari K, Jouvet A, Uro-Coste E, Martin-Duverneuil N, Sanson M, Delattre JY, Figarella-Branger D, de Reyniès A, Ducray F; POLA network.

Nat Commun. 2016 Apr 19;7:11263. doi: 10.1038/ncomms11263.

40.

Characteristics of gliomas in patients with somatic IDH mosaicism.

Bonnet C, Thomas L, Psimaras D, Bielle F, Vauléon E, Loiseau H, Cartalat-Carel S, Meyronet D, Dehais C, Honnorat J, Sanson M, Ducray F.

Acta Neuropathol Commun. 2016 Mar 31;4:31. doi: 10.1186/s40478-016-0302-y.

41.

Anti-NMDA-R encephalitis: Should we consider extreme delta brush as electrical status epilepticus?

Chanson E, Bicilli É, Lauxerois M, Kauffmann S, Chabanne R, Ducray F, Honnorat J, Clavelou P, Rosenberg S.

Neurophysiol Clin. 2016 Feb;46(1):17-25. doi: 10.1016/j.neucli.2015.12.009. Epub 2016 Feb 26.

PMID:
26922283
42.

Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics.

Mazzocco P, Barthélémy C, Kaloshi G, Lavielle M, Ricard D, Idbaih A, Psimaras D, Renard MA, Alentorn A, Honnorat J, Delattre JY, Ducray F, Ribba B.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):728-37. doi: 10.1002/psp4.54. Epub 2015 Oct 10.

43.

Pseudotumoral presentation of cerebral amyloid angiopathy-related inflammation.

Ronsin S, Deiana G, Geraldo AF, Durand-Dubief F, Thomas-Maisonneuve L, Formaglio M, Desestret V, Meyronet D, Nighoghossian N, Berthezène Y, Honnorat J, Ducray F.

Neurology. 2016 Mar 8;86(10):912-9. doi: 10.1212/WNL.0000000000002444. Epub 2016 Feb 5.

44.

Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.

Mazzocco P, Honnorat J, Ducray F, Ribba B.

Comput Math Methods Med. 2015;2015:297903. doi: 10.1155/2015/297903. Epub 2015 Dec 15.

45.

Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.

Henaine AM, Paubel N, Ducray F, Diebold G, Frappaz D, Guyotat J, Cartalat-Carel S, Aulagner G, Hartmann D, Honnorat J, Armoiry X.

J Clin Pharm Ther. 2016 Feb;41(1):47-53. doi: 10.1111/jcpt.12346. Epub 2016 Jan 8.

PMID:
26748577
46.

Bevacizumab in late-onset radiation-induced myelopathy.

Psimaras D, Tafani C, Ducray F, Leclercq D, Feuvret L, Delattre JY, Ricard D.

Neurology. 2016 Feb 2;86(5):454-7. doi: 10.1212/WNL.0000000000002345. Epub 2016 Jan 6.

PMID:
26740673
47.

CSF IgA NMDAR antibodies are potential biomarkers for teratomas in anti-NMDAR encephalitis.

Desestret V, Chefdeville A, Viaccoz A, Bost C, Ducray F, Picard G, Rogemond V, Chaffois MO, Blanc C, Bardel C, Treilleux I, Pascual O, Antoine JC, Delattre JY, Honnorat J.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 29;2(6):e166. doi: 10.1212/NXI.0000000000000166. eCollection 2015 Dec.

48.

Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome.

Laurencin C, André-Obadia N, Camdessanché JP, Mauguière F, Ong E, Vukusic S, Peter-Derex L, Meyronet D, Bouhour F, Vial C, Ducray F, Honnorat J, Petiot P.

Neurology. 2015 Dec 8;85(23):2076-8. doi: 10.1212/WNL.0000000000002037. Epub 2015 Sep 23. No abstract available.

PMID:
26400578
49.

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas.

Alentorn A, Dehais C, Ducray F, Carpentier C, Mokhtari K, Figarella-Branger D, Chinot O, Cohen-Moyal E, Ramirez C, Loiseau H, Elouahdani-Hamdi S, Beauchesne P, Langlois O, Desenclos C, Guillamo JS, Dam-Hieu P, Ghiringhelli F, Colin P, Godard J, Parker F, Dhermain F, Carpentier AF, Frenel JS, Menei P, Bauchet L, Faillot T, Fesneau M, Fontaine D, Motuo-Fotso MJ, Vauleon E, Gaultier C, Le Guerinel C, Gueye EM, Noel G, Desse N, Durando X, Barrascout E, Wager M, Ricard D, Carpiuc I, Delattre JY, Idbaih A; POLA Network.

Neurology. 2015 Oct 13;85(15):1325-31. doi: 10.1212/WNL.0000000000002014. Epub 2015 Sep 18.

50.

Clinical Spectrum of Encephalitis Associated With Antibodies Against the α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor: Case Series and Review of the Literature.

Joubert B, Kerschen P, Zekeridou A, Desestret V, Rogemond V, Chaffois MO, Ducray F, Larrue V, Daubail B, Idbaih A, Psimaras D, Antoine JC, Delattre JY, Honnorat J.

JAMA Neurol. 2015 Oct;72(10):1163-9. doi: 10.1001/jamaneurol.2015.1715. Review.

PMID:
26280228

Supplemental Content

Loading ...
Support Center